Searched for
GENERIC PROTONIX
Sun Pharma Q2 net profit quadruples to Rs 1,362 croreDrug major Sun Pharmaceutical Industries today posted a four-fold increase in consolidated net profit to Rs 1,362.30 crore for the second q...- Brokers’ Picks: MS overweight on Sun PharmaSettlement for generic Protonix patent litigation with Pfizer & Altana could negatively affect earnings estimate by 3 per cent to 4 per cent
- Sun Pharma litigation to impact earnings, P/E multiples: AnalystsAccording to analysts at CLSA, the litigation settlement is higher than expectation. They expect 2.5 per cent earnings downgrade on cash ou...
- Pfizer reaches $2 billion Protonix settlement with Teva and Sun PharmaJapan's Takeda Pharmaceutical Co Ltd, Pfizer's partner, will receive 36 per cent or about $774 million from the settlement.
- Sun Pharma: Strategic acquisitions to give drug firm a shot in the armGiven its past track record, investors can trust the company to go for strategically important acquisitions in its key markets.
- What Does Sun Pharma's September Quarter Performance Indicate?With Caraco resuming manufacturing at its facilities in Michigan, the company is likely to gradually recover any loss in revenues.
- Sun Pharma shares plunge on damages sought by WyethShares of Sun Pharmaceutical dropped nearly 3% as the company said that US-based Wyeth has sought damages worth $960 mn in a patent dispute.
- Wyeth makes $960 mn claims on Protonix patent case: Sun PharmaSun Pharma said US-based Wyeth Pharma has sought damages worth $960 mn related to their ongoing patent dispute over generic version of Prot...
- Wockhardt gets USFDA approval to market generic ProtonixThe company will manufacture the generic tablets at its US Food and Drug Administration's certified plant at Waluj, Maharashtra.
- Citigroup puts 'hold' on Sun PharmaWhile Sun is entitled to 180 days exclusivity, thanks to the long delay in getting approval and full genericisation of the capsule form lik...
- Emkay reduces Sun Pharma’s price target to Rs 1632Emkay Global Financial Services has maintained its Hold recommendation on Sun Pharma after two negative news reports for the company from t...
- Pharma cos wary of overseas deals on pricing pressureWhile pricing pressure both in the US and Europe is leading to lower profitability, companies are also suffering the impact of firmer rupee...
- Ranbaxy gets tentative FDA nod for ulcer drugNexium is the second largest selling drug in the world and has annual sales of $5.5 billion in the US market alone.
- Budget likely to scrap 16% excise on 7,000 drugsPrices of 7,000 drugs classified as 'essential medicines' are likely to witness a sharp fall after the forthcoming Budget. Corporate India ...
- Dr Reddy's plans to file 20 new drug applicationsDr Reddy’s Laboratories is betting on the US market and plans to file about 20 more ANDAs (Abbreviated New Drug Applications) in 2008. Reso...
- Sun basks in improved US salesSun Pharmaceuticals registered a spectacular performance during the December 2007 quarter
- Sun Pharma launches generic Protonix tabletsSun Pharmaceutical Industries Ltd on Wednesday commercially launched generic Pantoprazole Sodium Delayed Release tablets, 40 mg, which is A...
- Teva’s protonix version sale in US to hit SunIn a development which may impact Sun Pharma’s hopes of a windfall by selling generic versions of Wyeth’s $2.5-billion drug Protonix.
- Lupin wins Altace patent case in USIndia’s Lupin has won its patent challenge against King Pharmaceuticals and Sanofi-Aventis for blood pressure drug Altace, which has sales ...
- Sun Pharma gets US nod for pantropazoleThe approval for pantoprazole tablets, generic version of Wyeth's Protonix, is for multiple strengths of 20 mg and 40 mg.
Load More
